Compare Moody's Corporation (MCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Viatris Inc — how do they compare? Moody's Corporation trades at $477.76 (market cap $82.52B), while Viatris Inc trades at $16.32 (market cap $18.69B). The key difference: Moody's Corporation is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| MCO | VTRS | |
|---|---|---|
Market Cap | $82.52B | $18.69B |
Sector | Financials | Health |
52-Week High | $539.61 | $17.86 |
52-Week Low | $412.23 | $9.49 |
Enterprise Value | $88.54B | $30.80B |
Dividend Yield | 0.86% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $478.14, showing modest daily gains of 0.08%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust profitability metrics, including 34.25% net income margin and 80.15% ROE. Recent Q2 2026 results exceeded expectations with $4.68 EPS versus $4.26 expected, driven by strong analytics demand and debt issuance activity. Technical indicators remain neutral with support at $475 and resistance at $481.
MCO presents a compelling growth story with premium valuation justified by exceptional profitability and market leadership. The primary investment opportunity lies in sustained analytics growth and credit rating dominance, while risks include valuation sensitivity and potential debt market volatility. Analyst consensus remains bullish with $561.88 price target representing 17.5% upside potential from current levels.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
